Rising Incidences Of Alzheimer’s Is Expected To Foster The Growth Of Advanced Therapy Medicinal Products (ATMPs) Market

Advanced Therapy Medicinal Products (ATMPs) are innovative therapies that comprises cell therapy, gene therapy, and tissue engineered products. Cell therapy products include cellular immunotherapies and autologous and allogeneic cells for certain therapeutic indications including adult and embryonic stem cells. Whereas, Human gene therapy refers to products that introduce genetic material into individuals DNA to replace faulty or missing genetic material, thus treating a disease or abnormal medical condition. These are a novel class of medicines that offer potential treatment opportunities for diseases that have currently limited or no therapeutic options such as hemophilia, cystic fibrosis, metabolic disorders, muscular dystrophies, skin burns, Alzheimer, and cancer. Although majority of ATMPs are in an early stage of development, consolidated trial stage and the chances to cure chronic conditions signify that ATMPs may achieve the market sooner than standard treatments. Furthermore, advanced therapy medicinal products are regulated and authorized for marketing by the Food and Drug Administration (FDA) in the U.S. and by European Medicines Agency (EMA) in the Europe.

Get PDF of Brochure of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/1101

Advanced Therapy Medicinal Products Market Taxonomy:
Advanced therapy medicinal products are segmented on the basis of therapy, diseases, and geography

On the basis of products, the global advanced therapy medicinal products market are segmented into:
• Somatic Cell Therapy Medicinal Products
• Tissue Engineered Medicinal Products
• Gene Therapy Medicinal Products
On the basis of diseases, the global advanced therapy medicinal products market are segmented into:
• Alzheimer’s
• Cystic Fibrosis
• Muscular Dystrophies
• Hemophilia

Strategic acquisitions by Pfizer to develop gene therapies for the treatment of neuromuscular conditions to enhance the competitive environment

The key players operating the advanced therapy medicinal products market include Uniqure, Pfizer, Bluebird Bio Inc., BioMarin Pharmaceutical, Novartis AG, GE Healthcare, Shire Biotechnology, and Kite Pharma. The key players are focusing on strategic mergers and acquisition and development of innovative products. For instance, Pfizer acquired Bamboo Therapeutics, a biotechnology company focused on developing gene therapies for the treatment of patients with diseases related to neuromuscular conditions and the diseases affecting central nervous system. The acquisition is expected to significantly expand Pfizer’s expertise in gene therapy by providing clinical and pre-clinical assets to balance the rare disease portfolio of company with advanced recombinant Adeno Associated Virus vector design and production technology, which is fully functional phase I/II gene therapy with manufacturing facilities.

Get Best Discount on Research Report before Purchase: https://www.coherentmarketinsights.com/insight/request-discount/1101

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.